About Lantheus (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Diagnostic substances
Trailing P/E Ratio15.20
Forward P/E Ratio17.85
Sales & Book Value
Annual Sales$331.38 million
Price / Sales1.77
Cash Flow$1.6758 per share
Price / Cash9.16
Book Value$0.62 per share
Price / Book24.76
EPS (Most Recent Fiscal Year)$1.00
Net Income$123.38 million
Return on Equity-145.14%
Return on Assets11.84%
Lantheus (NASDAQ:LNTH) Frequently Asked Questions
What is Lantheus' stock symbol?
Lantheus trades on the NASDAQ under the ticker symbol "LNTH."
How were Lantheus' earnings last quarter?
Lantheus Holdings Inc (NASDAQ:LNTH) posted its quarterly earnings data on Wednesday, May, 2nd. The medical equipment provider reported $0.22 EPS for the quarter, hitting analysts' consensus estimates of $0.22. The medical equipment provider had revenue of $82.63 million for the quarter, compared to analyst estimates of $81.15 million. Lantheus had a negative return on equity of 145.14% and a net margin of 38.32%. The business's revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.11 earnings per share. View Lantheus' Earnings History.
What price target have analysts set for LNTH?
4 brokerages have issued 12-month price targets for Lantheus' stock. Their forecasts range from $22.00 to $27.00. On average, they anticipate Lantheus' share price to reach $24.00 in the next year. View Analyst Ratings for Lantheus.
Are investors shorting Lantheus?
Lantheus saw a drop in short interest in May. As of May 31st, there was short interest totalling 365,314 shares, a drop of 45.2% from the May 15th total of 666,888 shares. Based on an average daily trading volume, of 411,058 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.0% of the shares of the stock are short sold.
Who are some of Lantheus' key competitors?
Some companies that are related to Lantheus include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Akers Biosciences (AKER), Arca Biopharma (ABIO), GeneNews (GNWSF), Achieve Life Sciences (ACHV) and Fluoropharma Medical (FPMI).
Who are Lantheus' key executives?
Lantheus' management team includes the folowing people:
- Ms. Mary Anne Heino, CEO, Pres & Director (Age 58)
- Mr. John W. Crowley, CFO & Treasurer (Age 54)
- Mr. Michael P. Duffy, Sr. VP of Strategy & Bus. Devel., Gen. Counsel and Sec. (Age 57)
- Mr. Timothy G. Healey, Sr. VP of Commercial (Age 52)
- Mr. William C. Dawes Jr., VP of Manufacturing and Operations (Age 46)
When did Lantheus IPO?
(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.
Has Lantheus been receiving favorable news coverage?
Media coverage about LNTH stock has trended positive on Monday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Lantheus earned a daily sentiment score of 0.34 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 43.35 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Lantheus?
Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lantheus' stock price today?
One share of LNTH stock can currently be purchased for approximately $15.35.
How big of a company is Lantheus?
Lantheus has a market capitalization of $555.07 million and generates $331.38 million in revenue each year. The medical equipment provider earns $123.38 million in net income (profit) each year or $1.00 on an earnings per share basis. Lantheus employs 483 workers across the globe.
How can I contact Lantheus?
Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]
MarketBeat Community Rating for Lantheus (LNTH)MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.